According to the Zhitong Finance App, Insili Intelligence (03696.HK) announced that the company nominated ISM9546 as a pre-clinical candidate compound (PCC). It is an innovative, oral, peripherally restricted VAV1 molecular gel degrader, which is potentially used in the treatment of various autoimmune diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Powered by Insili Smart's proprietary Pharma.ai solution, ISM9546 is not only the 35th PCC nominated by the company since 2021, but also balances efficacy and safety, shows nanomolar activity in multiple cell experiments, and potentially reduces risks associated with the central nervous system (CNS) through its peripheral restrictive properties.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.